Studies have shown that hyperglycemia in T2DM patients induces an increase in reactive oxygen species (ROS) in myeloid cells, leading to enhanced production of IL-1β and IL-18, which are inflammasome-dependent. Here, IL1B is linked to Hyperglycemia.